NEWS
Predictive Oncology Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery
Predictive Oncology (NASDAQ: POAI) has launched a unique 3D cell culture model to enhance cancer drug discovery and future drug development. These organ-specific in vitro models better mimic human tissue compared to traditional 2D assays, allowing for more accurate clinical outcome predictions and optimized candidate selection for clinical trials.
The global 3D cell culture market is projected to grow from $1.4 billion in 2022 to nearly $5.3 billion by 2032, driven by applications in pharmaceuticals, regenerative medicine, cancer research, and toxicology. The technology aims to reduce time-to-market and costs, decrease animal testing, and improve clinical trial efficiency.
The company's efforts in developing 3D organoids and spheroids, enhanced by AI and machine learning, have shown promising results, with recent presentations at the Society for Laboratory Automation and Screening (SLAS) in Boston.
The global 3D cell culture market is projected to grow from $1.4 billion in 2022 to nearly $5.3 billion by 2032, driven by applications in pharmaceuticals, regenerative medicine, cancer research, and toxicology. The technology aims to reduce time-to-market and costs, decrease animal testing, and improve clinical trial efficiency.
The company's efforts in developing 3D organoids and spheroids, enhanced by AI and machine learning, have shown promising results, with recent presentations at the Society for Laboratory Automation and Screening (SLAS) in Boston.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1052Followers
65Following
7153Visitors
Follow